16. Lars SØrensen
bpoy lars sorensen

CEO, Novo Nordisk

Sørensen isn't afraid to take calculated risks: Five years ago he jettisoned the drug maker's diabetes-pill research (while others were pouring money into it), betting instead that injected insulin would continue to be the most effective diabetes treatment. The bet paid off. The pill market shrank because of safety worries and patent expirations, and today Novo Nordisk is the world's biggest insulin producer. Sørensen has positioned the Danish company to keep profiting from the global epidemic: degludec, a new diabetes drug, is close to winning approvals. --OA

- Last updated November 30 2012 05:12 PM ET
Join the Conversation
Amazon's Jeff Bezos: The ultimate disrupter

He's a pro-customer, tightfisted risk-taker who is conditioning Wall Street to embrace his erratic earnings. If you're running a business with high margins - watch out.

Market indexes are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer LIBOR Warning: Neither BBA Enterprises Limited, nor the BBA LIBOR Contributor Banks, nor Reuters, can be held liable for any irregularity or inaccuracy of BBA LIBOR. Disclaimer. Morningstar: © 2014 Morningstar, Inc. All Rights Reserved. Disclaimer The Dow Jones IndexesSM are proprietary to and distributed by Dow Jones & Company, Inc. and have been licensed for use. All content of the Dow Jones IndexesSM © 2014 is proprietary to Dow Jones & Company, Inc. Chicago Mercantile Association. The market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. FactSet Research Systems Inc. 2014. All rights reserved. Most stock quote data provided by BATS.